Baxter International (BAX) Stock Forecast & Price Target

Compare

1,575 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BAX Analyst Ratings

Hold

2 Buy

9 Hold

1 Sell

Based on 12 analysts giving stock ratings to

Baxter

International

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BAX Stock 12 Month Forecast

Average Price Target

$21.73

▲(5.03% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Baxter International in the last 3 months. The average price target is $21.73 with a high forecast of $30.00 and a low forecast of $15.00. The average price target represents a 5.03% change from the last price of $20.69.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","25":"$25","36":"$36","19.5":"$19.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,19.5,25,30.5,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.11,19.947692307692307,20.785384615384615,21.623076923076923,22.46076923076923,23.298461538461538,24.136153846153846,24.973846153846154,25.81153846153846,26.64923076923077,27.486923076923077,28.324615384615385,29.162307692307692,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.11,19.31153846153846,19.513076923076923,19.714615384615385,19.916153846153847,20.11769230769231,20.31923076923077,20.52076923076923,20.72230769230769,20.923846153846153,21.125384615384615,21.326923076923077,21.52846153846154,{"y":21.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.11,18.793846153846154,18.47769230769231,18.161538461538463,17.845384615384614,17.529230769230768,17.213076923076922,16.896923076923077,16.58076923076923,16.264615384615386,15.948461538461538,15.632307692307691,15.316153846153846,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.052,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":32.953,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":28.641,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.981,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.061,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.578,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.271,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.328,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.996,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.795,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.347,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.08,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.11,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$21.73

Lowest Price Target$15.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Roman

Goldman Sachs

$22→$23

Hold

11.16%

Upside

Reiterated

01/09/26

Baxter price target raised to $23 from $22 at Goldman SachsBaxter price target raised to $23 from $22 at Goldman Sachs

Matt Miksic

Barclays

$36→$30

Buy

45.00%

Upside

Reiterated

01/08/26

Barclays Sticks to Their Buy Rating for Baxter International (BAX)

Travis Steed

Bank of America Securities

$24

Hold

16.00%

Upside

Reiterated

01/05/26

Bank of America Securities Reaffirms Their Hold Rating on Baxter International (BAX)

Vijay Kumar

Evercore ISI

$24→$23

Buy

11.16%

Upside

Reiterated

01/05/26

Baxter price target lowered to $23 from $24 at Evercore ISIBaxter price target lowered to $23 from $24 at Evercore ISI

Larry Biegelsen

Wells Fargo

$21→$19

Hold

-8.17%

Downside

Reiterated

12/12/25

Baxter International (BAX) Gets a Hold from Wells Fargo

Joanne Wuensch

Citi

$21

Hold

1.50%

Upside

Reiterated

12/11/25

Citi opens 'upside 90-day catalyst watch' on BaxterCiti opens 'upside 90-day catalyst watch' on Baxter

Patrick Wood

Morgan Stanley

$19→$15

Sell

-27.50%

Downside

Reiterated

12/02/25

Baxter price target lowered to $15 from $19 at Morgan StanleyBaxter price target lowered to $15 from $19 at Morgan Stanley

Danielle Antalffy

UBS

$24→$21

Hold

1.50%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH), Baxter International (NYSE: BAX) and Illumina (NASDAQ: ILMN)

Robbie Marcus

J.P. Morgan

$19

Hold

-8.17%

Downside

Reiterated

10/30/25

Baxter International (BAX) Gets a Hold from J.P. Morgan

Josh Jennings

TD Cowen

$26→$22

Hold

6.33%

Upside

Reiterated

10/30/25

Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (NASDAQ: KYTX), Disc Medicine (NASDAQ: IRON) and Baxter International (NYSE: BAX)

Steven Silver

Argus Research

Hold

―

Downgraded

10/30/25

Baxter downgraded to Hold from Buy at ArgusBaxter downgraded to Hold from Buy at Argus

Rick Wise

Stifel Nicolaus

$25→$22

Hold

6.33%

Upside

Reiterated

10/30/25

Baxter price target lowered to $22 from $25 at StifelBaxter price target lowered to $22 from $25 at Stifel

Jayson Bedford

Raymond James

Hold

―

Reiterated

08/01/25

Matthew Taylor

Jefferies

Hold

―

Reiterated

05/02/25

Analysts Offer Insights on Healthcare Companies: GeoVax Labs (NASDAQ: GOVX) and Baxter International (NYSE: BAX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Roman

Goldman Sachs

$22→$23

Hold

11.16%

Upside

Reiterated

01/09/26

Baxter price target raised to $23 from $22 at Goldman SachsBaxter price target raised to $23 from $22 at Goldman Sachs

Matt Miksic

Barclays

$36→$30

Buy

45.00%

Upside

Reiterated

01/08/26

Barclays Sticks to Their Buy Rating for Baxter International (BAX)

Travis Steed

Bank of America Securities

$24

Hold

16.00%

Upside

Reiterated

01/05/26

Bank of America Securities Reaffirms Their Hold Rating on Baxter International (BAX)

Vijay Kumar

Evercore ISI

$24→$23

Buy

11.16%

Upside

Reiterated

01/05/26

Baxter price target lowered to $23 from $24 at Evercore ISIBaxter price target lowered to $23 from $24 at Evercore ISI

Larry Biegelsen

Wells Fargo

$21→$19

Hold

-8.17%

Downside

Reiterated

12/12/25

Baxter International (BAX) Gets a Hold from Wells Fargo

Joanne Wuensch

Citi

$21

Hold

1.50%

Upside

Reiterated

12/11/25

Citi opens 'upside 90-day catalyst watch' on BaxterCiti opens 'upside 90-day catalyst watch' on Baxter

Patrick Wood

Morgan Stanley

$19→$15

Sell

-27.50%

Downside

Reiterated

12/02/25

Baxter price target lowered to $15 from $19 at Morgan StanleyBaxter price target lowered to $15 from $19 at Morgan Stanley

Danielle Antalffy

UBS

$24→$21

Hold

1.50%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH), Baxter International (NYSE: BAX) and Illumina (NASDAQ: ILMN)

Robbie Marcus

J.P. Morgan

$19

Hold

-8.17%

Downside

Reiterated

10/30/25

Baxter International (BAX) Gets a Hold from J.P. Morgan

Josh Jennings

TD Cowen

$26→$22

Hold

6.33%

Upside

Reiterated

10/30/25

Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (NASDAQ: KYTX), Disc Medicine (NASDAQ: IRON) and Baxter International (NYSE: BAX)

Steven Silver

Argus Research

Hold

―

Downgraded

10/30/25

Baxter downgraded to Hold from Buy at ArgusBaxter downgraded to Hold from Buy at Argus

Rick Wise

Stifel Nicolaus

$25→$22

Hold

6.33%

Upside

Reiterated

10/30/25

Baxter price target lowered to $22 from $25 at StifelBaxter price target lowered to $22 from $25 at Stifel

Jayson Bedford

Raymond James

Hold

―

Reiterated

08/01/25

Matthew Taylor

Jefferies

Hold

―

Reiterated

05/02/25

Analysts Offer Insights on Healthcare Companies: GeoVax Labs (NASDAQ: GOVX) and Baxter International (NYSE: BAX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Baxter International

3 Months

xxx

Success Rate

6/25 ratings generated profit

Average Return

-5.16%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 24.00% of your transactions generating a profit, with an average return of -5.16% per trade.

1 Year

Matt MiksicBarclays

Success Rate

7/25 ratings generated profit

Average Return

-8.80%

reiterated a buy rating 4 days ago

Copying Matt Miksic's trades and holding each position for 1 Year would result in 28.00% of your transactions generating a profit, with an average return of -8.80% per trade.

2 Years

xxx

Success Rate

4/25 ratings generated profit

Average Return

-17.34%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 16.00% of your transactions generating a profit, with an average return of -17.34% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BAX Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Oct 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BAX has received 5 Buy Ratings, 18 Hold Ratings, and 2 Sell Ratings. BAX average Analyst price target in the past 3 months is 21.73.

Each month's total comprises the sum of three months' worth of ratings.

BAX Financial Forecast

BAX Earnings Forecast

Next quarter’s earnings estimate for BAX is $0.54 with a range of $0.52 to $0.56. The previous quarter’s EPS was $0.69. BAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year BAX has Performed in-line its overall industry.

BAX Sales Forecast

Next quarter’s sales forecast for BAX is $2.84B with a range of $2.80B to $3.04B. The previous quarter’s sales results were $2.83B. BAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year BAX has Performed in-line its overall industry.

BAX Stock Forecast FAQ

What is BAX’s average 12-month price target, according to analysts?

Based on analyst ratings, Baxter International’s 12-month average price target is 21.73.

What is BAX’s upside potential, based on the analysts’ average price target?

Baxter International has 5.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BAX a Buy, Sell or Hold?

Baxter International has a consensus rating of Hold which is based on 2 buy ratings, 9 hold ratings and 1 sell ratings.

What is Baxter International’s price target?

The average price target for Baxter International is 21.73. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $15.00. The average price target represents 5.03% Increase from the current price of $20.69.

What do analysts say about Baxter International?

Baxter International’s analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of BAX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Baxter International (BAX) Stock Forecast & Price Target

BAX Analyst Ratings

BAX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Baxter International

BAX Analyst Recommendation Trends

BAX Financial Forecast

BAX Earnings Forecast

BAX Sales Forecast

BAX Stock Forecast FAQ

Detailed List of Analyst Forecasts